For the past few years, benefits consultants have spent considerable energy helping employers understand and navigate the dynamic GLP-1 landscape. It’s a space moving faster than most can keep up with: new drugs entering the market, new indications and mounting cost pressures.
Initially, employers grappled with the dilemma of whether to cover GLP-1s. Notably, the conversation has shifted with employers and benefits leaders are now trending in favor of coverage, settling this conundrum.
